Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Earnings Results, Hits Estimates

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) released its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03), FiscalAI reports. Lineage Cell Therapeutics had a negative return on equity of 73.06% and a negative net margin of 246.58%. The firm had revenue of $1.43 million during the quarter, compared to analyst estimates of $2.32 million.

Lineage Cell Therapeutics Trading Down 10.8%

LCTX traded down $0.12 on Thursday, hitting $0.99. 1,350,205 shares of the company’s stock traded hands, compared to its average volume of 1,287,877. The company’s 50 day simple moving average is $1.00 and its 200-day simple moving average is $1.30. Lineage Cell Therapeutics has a one year low of $0.88 and a one year high of $1.99. The firm has a market cap of $250.46 million, a price-to-earnings ratio of -5.21 and a beta of 1.68.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.